Azenta, Inc. ( AZTA ) NASDAQ Global Select

Cena: 33.23 ( 1.16% )

Aktualizacja 07-03 22:00
NASDAQ Global Select
Branża: Medical - Instruments & Supplies
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Instruments & Supplies
Zatrudnienie: 3 300
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98%
Ilość akcji: 55 765 100
Debiut giełdowy: 1995-02-02
WWW: https://www.azenta.com
CEO: Mr. John P. Marotta
Adres: 15 Elizabeth Drive
Siedziba: 01824 Chelmsford
ISIN: US1143401024
Opis firmy:

Azenta, Inc. zapewnia rozwiązania eksploracji i zarządzania naukami naukami życia na rynku nauk przyrodniczych w Ameryce Północnej, Europie, Chinach, Azji i na arenie międzynarodowej. Firma działa za pośrednictwem dwóch segmentów zgłaszanych, produktów nauk przyrodniczych i usług nauk przyrodniczych. Segment produktów nauk przyrodniczych oferuje zautomatyzowane systemy zarządzania próbkami zimnej do przechowywania złożonych i biologicznych próbek; sprzęt do przygotowania i obsługi próbki; materiały eksploatacyjne; oraz instrumenty, które pomagają klientom w zarządzaniu próbkami podczas wykrywania badań i przepływów pracy. Segment usług nauk przyrodniczych zapewnia kompleksowe programy zarządzania próbkami, zintegrowane rozwiązania łańcucha chłodniczego, informatyki i próby oparte na próbie usługi laboratoryjne w celu rozwoju badań naukowych i wspierania rozwoju leków. Usługi tego segmentu obejmują przechowywanie próbek, sekwencjonowanie genomowe, syntezę genów, przetwarzanie laboratoryjne, analizę laboratoryjną, zamówienia biospecimenowe i inne usługi wsparcia. Obsługuje szereg klientów nauk o życiu, w tym firmy farmaceutyczne, firmy biotechnologiczne, biorepozytoria i instytuty badawcze. Firma była wcześniej znana jako Brooks Automation, Inc. i zmieniła nazwę na Azenta, Inc. w grudniu 2021 r. Azenta, Inc. została założona w 1978 roku i ma siedzibę w Chelmsford, Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 1 521 266 077
Aktywa: 2 100 041 000
Cena: 33.23
Wskaźnik Altman Z-Score: 5.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -10.2
Ilość akcji w obrocie: 98%
Średni wolumen: 1 010 754
Ilość akcji 45 779 900
Wskaźniki finansowe
Przychody TTM 656 323 000
Zobowiązania: 331 074 000
Przedział 52 tyg.: 23.91 - 63.58
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: -3.3
P/E branży: 29.9
Beta: 1.483
Raport okresowy: 2025-08-04
WWW: https://www.azenta.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jason W. Joseph Senior Vice President, General Counsel & Corporate Secretary 544 127 1971
Mr. Robin Vacha Senior Vice President of Global Operations 533 352 1976
Dr. Stephen S. Schwartz Chief Executive Officer & President 1 054 425 1959
Mr. John E. O'Brien Senior Vice President of Corporate Development 0 1970
Ms. Violetta Hughes Vice President & Chief Accounting Officer 0 1972
Mr. J. Robert Woodward Senior Vice President of Global Quality & Regulatory 0 0
Ms. Olga Pirogova Senior Vice President & Chief HR Officer 0 1974
Dr. Ginger Zhou Ph.D. Senior Vice President & GM of Multiomics and Synthesis Solutions 0 1977
Mr. Herman Cueto Executive Vice President & Chief Financial Officer 0 1974
Mr. Michael Paulo Vice President and Chief Information & Digital Officer 0 0
Wiadomości dla Azenta, Inc.
Tytuł Treść Źródło Aktualizacja Link
Azenta Life Sciences and Form Bio Announce Strategic Partnership to Advance AAV Gene Therapy Development Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass. prnewswire.com 2025-05-13 20:05:00 Czytaj oryginał (ang.)
Azenta, Inc. (AZTA) Q2 2025 Earnings Call Transcript Azenta, Inc. (NASDAQ:AZTA ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Yvonne Perron - Vice President, Financial Planning & Analysis and Investor Relations John Marotta - President and Chief Executive Officer Lawrence Lin - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company, LLC Vijay Kumar - Evercore Inc. Paul Knight - KeyBanc Capital Markets Inc. Matthew Stanton - Jefferies Group LLC Brendan Smith - TD Cowen Operator Greetings, and welcome to the Azenta Q2 2025 Financial Results. During the presentation, all participants will be in a listen-only mode. seekingalpha.com 2025-05-07 17:44:19 Czytaj oryginał (ang.)
Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 BURLINGTON, Mass. , May 7, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. prnewswire.com 2025-05-07 10:30:00 Czytaj oryginał (ang.)
Azenta Announces Fiscal 2025 Second Quarter Earnings Conference Call and Webcast BURLINGTON, Mass. , April 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2025 earnings which ended on March 31, 2025, on Wednesday May 7, 2025, before the market opens. prnewswire.com 2025-04-24 20:15:00 Czytaj oryginał (ang.)
Azenta Publishes its 2024 Environmental, Social, & Governance (ESG) Report BURLINGTON, Mass. , March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. prnewswire.com 2025-03-24 18:05:00 Czytaj oryginał (ang.)
Azenta to Participate in the Virtual KeyBanc Capital Markets Healthcare Forum BURLINGTON, Mass. , March 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) announced that Lawrence Y. prnewswire.com 2025-03-10 19:05:00 Czytaj oryginał (ang.)
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock? Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately. zacks.com 2025-03-06 15:10:16 Czytaj oryginał (ang.)
Azenta, Inc. (AZTA) Q1 2025 Earnings Call Transcript Azenta, Inc. (NASDAQ:AZTA ) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Yvonne Perron - Vice President, FP&A & Investor Relations John Marotta - President & Chief Executive Officer Lawrence Lin - Executive Vice President & Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens David Saxon - Needham & Company Vijay Kumar - Evercore ISI Matt Stanton - Jefferies Paul Knight - KeyBanc Capital Markets Andrew Cooper - Raymond James Operator Greetings and welcome to the Azenta Q1 2025 Financial Results Conference Call. During the presentation, all participants will be in a listen-only mode. seekingalpha.com 2025-02-05 16:33:04 Czytaj oryginał (ang.)
Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024 BURLINGTON, Mass. , Feb. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2024. prnewswire.com 2025-02-05 09:00:00 Czytaj oryginał (ang.)
Azenta Announces the Election of Dipal Doshi to its Board of Directors BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board of Directors at its Annual Meeting of Stockholders held earlier today. prnewswire.com 2025-01-30 18:05:00 Czytaj oryginał (ang.)
Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call and Webcast BURLINGTON, Mass. , Jan. 27, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2025 earnings which ended on December 31, 2024, on Wednesday February 5, 2025, before the market opens. prnewswire.com 2025-01-27 18:05:00 Czytaj oryginał (ang.)
UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence BURLINGTON, Mass. , Jan. 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has been selected as the technology provider by UK Biocentre as they expand their large-scale sample storage in support of the preservation of internationally significant sample collections. prnewswire.com 2025-01-23 18:05:00 Czytaj oryginał (ang.)
Azenta (AZTA) Surges 7.2%: Is This an Indication of Further Gains? Azenta (AZTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com 2024-12-19 06:35:21 Czytaj oryginał (ang.)
Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600 NEW YORK , Nov. 19, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Flex Ltd (NASD: FLEX) will replace Azenta Inc. (NASD: AZTA) in the S&P MidCap 400, and Azenta will replace Envestnet Inc. (NYSE: ENV) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, November 25. Bain Capital is acquiring Envestnet in a deal expected to be completed soon, pending final closing conditions. prnewswire.com 2024-11-19 19:56:00 Czytaj oryginał (ang.)
Azenta to Participate in Stephens Annual Investment Conference BURLINGTON, Mass. , Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. prnewswire.com 2024-11-14 10:00:00 Czytaj oryginał (ang.)
Azenta, Inc. (AZTA) Q4 2024 Earnings Call Transcript Azenta, Inc. (NASDAQ:AZTA ) Q4 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations John Marotta - President and Chief Executive Officer Herman Cueto - Executive Vice President and Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Vijay Kumar - Evercore ISI Jacob Johnson - Stephens Andrew Cooper - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings and welcome to the Azenta Fourth Quarter 2024 Financial Results. During the presentation, all lines will be in a listen-only mode. seekingalpha.com 2024-11-13 00:09:59 Czytaj oryginał (ang.)
Azenta (AZTA) Q4 Earnings Top Estimates Azenta (AZTA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago. zacks.com 2024-11-12 20:55:18 Czytaj oryginał (ang.)
Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transition BURLINGTON, Mass. prnewswire.com 2024-11-12 18:05:00 Czytaj oryginał (ang.)
Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast BURLINGTON, Mass. , Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes. prnewswire.com 2024-11-04 18:05:00 Czytaj oryginał (ang.)
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test BURLINGTON, Mass. , Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. prnewswire.com 2024-10-30 18:05:00 Czytaj oryginał (ang.)
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P. prnewswire.com 2024-09-04 12:00:00 Czytaj oryginał (ang.)
GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event BURLINGTON, Mass. , Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20. prnewswire.com 2024-08-12 20:05:00 Czytaj oryginał (ang.)
Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript Azenta, Inc. (NASDAQ:AZTA ) Q3 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Sophia Knopp - Evercore ISI Noah Lewis - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings, and welcome to the Azenta Third Quarter 2024 Financial Results. [Operator Instructions]. seekingalpha.com 2024-08-06 23:40:26 Czytaj oryginał (ang.)
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates Azenta (AZTA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago. zacks.com 2024-08-06 23:15:48 Czytaj oryginał (ang.)
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024 BURLINGTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024. prnewswire.com 2024-08-06 20:05:00 Czytaj oryginał (ang.)
Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference BURLINGTON, Mass. , Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024. prnewswire.com 2024-08-05 20:05:00 Czytaj oryginał (ang.)
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-07-30 15:07:04 Czytaj oryginał (ang.)
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock? Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately. zacks.com 2024-07-30 14:01:23 Czytaj oryginał (ang.)
Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast BURLINGTON, Mass. , July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes. prnewswire.com 2024-07-24 20:05:00 Czytaj oryginał (ang.)
FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study Azenta will provide proteomics technology profiling on up to 20,000 individuals. BURLINGTON, Mass. prnewswire.com 2024-07-22 20:05:00 Czytaj oryginał (ang.)
New Strong Buy Stocks for July 16th BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024. zacks.com 2024-07-16 10:10:37 Czytaj oryginał (ang.)
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass. , June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn's disease and ulcerative colitis. prnewswire.com 2024-06-04 20:05:00 Czytaj oryginał (ang.)